<DOC>
	<DOCNO>NCT01423604</DOCNO>
	<brief_summary>The purpose study determine whether ruxolitinib add capecitabine effective improve overall survival patient metastatic pancreatic cancer .</brief_summary>
	<brief_title>Study Ruxolitinib Pancreatic Cancer Patients</brief_title>
	<detailed_description>The study consist open-label , safety run-in period compose 1 patient cohort 9 patients/cohort . This phase study determine safety capecitabine/ruxolitinib combination patient population . A randomized , double-blind study two treatment arm conduct safety run-in result first part study show capecitabine/ruxolitinib combination safe additional patient could treat . All patient receive capecitabine therapy addition ruxolitinib placebo ( Study Drug ) . Treatment patient consist repeat 21-day cycle . Capecitabine self-administered first 14 day cycle , Study Drug self-administered entire 21-day cycle . Treatment cycle continue long regimen tolerate patient meet discontinuation criterion . In event disease progression , capecitabine therapy discontinue Study Drug could continue administer . Subjects discontinue treatment Study Drug continue follow obtain information regard subsequent treatment regimen survival .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>18 year age old Diagnosis metastatic pancreatic cancer ; subject must measurable , evaluable disease histologically confirm Karnofsky performance status ≥ 60 Subjects must fail 1stline gemcitabine treatment metastatic pancreatic cancer : An alternate chemotherapeutic agent acceptable substitute 1stline therapy event subject intolerant ineligible receive gemcitabine ≥ 2 week elapse completion previous chemotherapy , subject must recover new stable baseline relate toxicity More 1 prior chemotherapy regimen ( include adjuvant therapy ) metastatic disease Evidence central nervous system ( CNS ) metastases ( unless stable &gt; 3 month ) history uncontrolled seizure Ongoing radiation therapy prior radiation therapy administer secondline treatment Other active malignancy except basal squamous carcinoma skin Inability swallow food condition upper GI tract preclude administration oral medication Inadequate renal , hepatic bone marrow function demonstrate clinical observation and/or laboratory assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic pancreatic cancer</keyword>
</DOC>